A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer

D. L. Ahmann, Daniel J Schaid, J. N. Ingle, H. F. Bisel, A. J. Schutt, Jan Craig Buckner, H. J. Long, J. Rubin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Ninety-four patients were entered in a clinical trial assessing the clinical activity of cyclophosphamide, doxorubicin, and prednisone (CAP) versus a combination of cyclophosphamide, 5-Flurouracil, and prednisone (CFP) in patients with advanced breast cancer. Objective response rates were comparable, 49% for CFP and 46% for CAP. There was no statistical difference between the duration of response of the two regimens or in time to progression. Most importantly, survival differences were not apparent. Both regimens were clinically tolerable and toxicities, for the most part, were comparable. Thus, no therapeutic advantage existed for either of these polychemotherapy regimens in patients with advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)179-183
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume14
Issue number3
StatePublished - 1991

Fingerprint

Prednisone
Fluorouracil
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Combination Drug Therapy
Clinical Trials
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{af674092e2ba487bbec5e0d6d1b7fbe4,
title = "A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer",
abstract = "Ninety-four patients were entered in a clinical trial assessing the clinical activity of cyclophosphamide, doxorubicin, and prednisone (CAP) versus a combination of cyclophosphamide, 5-Flurouracil, and prednisone (CFP) in patients with advanced breast cancer. Objective response rates were comparable, 49{\%} for CFP and 46{\%} for CAP. There was no statistical difference between the duration of response of the two regimens or in time to progression. Most importantly, survival differences were not apparent. Both regimens were clinically tolerable and toxicities, for the most part, were comparable. Thus, no therapeutic advantage existed for either of these polychemotherapy regimens in patients with advanced breast cancer.",
author = "Ahmann, {D. L.} and Schaid, {Daniel J} and Ingle, {J. N.} and Bisel, {H. F.} and Schutt, {A. J.} and Buckner, {Jan Craig} and Long, {H. J.} and J. Rubin",
year = "1991",
language = "English (US)",
volume = "14",
pages = "179--183",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer

AU - Ahmann, D. L.

AU - Schaid, Daniel J

AU - Ingle, J. N.

AU - Bisel, H. F.

AU - Schutt, A. J.

AU - Buckner, Jan Craig

AU - Long, H. J.

AU - Rubin, J.

PY - 1991

Y1 - 1991

N2 - Ninety-four patients were entered in a clinical trial assessing the clinical activity of cyclophosphamide, doxorubicin, and prednisone (CAP) versus a combination of cyclophosphamide, 5-Flurouracil, and prednisone (CFP) in patients with advanced breast cancer. Objective response rates were comparable, 49% for CFP and 46% for CAP. There was no statistical difference between the duration of response of the two regimens or in time to progression. Most importantly, survival differences were not apparent. Both regimens were clinically tolerable and toxicities, for the most part, were comparable. Thus, no therapeutic advantage existed for either of these polychemotherapy regimens in patients with advanced breast cancer.

AB - Ninety-four patients were entered in a clinical trial assessing the clinical activity of cyclophosphamide, doxorubicin, and prednisone (CAP) versus a combination of cyclophosphamide, 5-Flurouracil, and prednisone (CFP) in patients with advanced breast cancer. Objective response rates were comparable, 49% for CFP and 46% for CAP. There was no statistical difference between the duration of response of the two regimens or in time to progression. Most importantly, survival differences were not apparent. Both regimens were clinically tolerable and toxicities, for the most part, were comparable. Thus, no therapeutic advantage existed for either of these polychemotherapy regimens in patients with advanced breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025916094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025916094&partnerID=8YFLogxK

M3 - Article

C2 - 2031502

AN - SCOPUS:0025916094

VL - 14

SP - 179

EP - 183

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 3

ER -